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Abstract
Background: Current guidelines recommend treatment of significant coronary artery disease by concomitant
coronary artery bypass grafting (CABG) in patients undergoing surgical aortic valve replacement. However there
is no consensus as to how best to treat coronary disease in high-risk patients requiring transcatheter aortic valve
implantation (TAVI).
Methods/Design: The percutaneous coronary intervention prior to transcatheter aortic valve implantation
(ACTIVATION) trial is a randomized, controlled open-label trial of 310 patients randomized to treatment of significant
coronary artery disease by percutaneous coronary intervention (PCI - test arm) or no PCI (control arm). Significant
coronary disease is defined as ≥1 lesion of ≥70% severity in a major epicardial vessel or 50% in a vein graft or protected
left main stem lesion. The trial tests the hypothesis that the strategy of performing pre-TAVI PCI is non-inferior to not
treating such coronary stenoses with PCI prior to TAVI, with a composite primary outcome of 12-month mortality and
rehospitalization. Secondary outcomes include efficacy end-points such as 30-day mortality, safety endpoints including
bleeding, burden of symptoms, and quality of life (assessed using the Seattle Angina Questionnaire and the Kansas City
Cardiomyopathy Questionnaire).
In conclusion, we hope that using a definition of coronary artery disease severity closer to that used in everyday practice
by interventional cardiologists - rather than the 50% severity used in surgical guidelines - will provide robust evidence to
direct guidelines regarding TAVI therapy and improve its safety and efficacy profile of this developing technique.
Trial registration: ISRCTN75836930, http://www.controlled-trials.com/ISRCTN75836930 (registered 19 November 2011).
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Background
Transcatheter aortic valve implantation (TAVI) has moved
into the cardiology mainstream with rapid acceptance of
this new technology since the first implant in 2002 [1].
The two devices with the largest experiences are the
self-expanding CoreValve Revalving™ system (Medtronic
CoreValve, Luxembourg) and the balloon expandable
Edwards Sapien XT valve (Edwards Lifesciences, Irvine,
CA). Both are employed in patients whose peri-operative
risk is deemed too high for surgical aortic valve replacement
(sAVR). Coronary artery disease has a high prevalence in
these patients [2-5] and shares many of the same causative
factors [6]. While the matrices for these devices state that
significant coronary artery disease (CAD) should preferably
be treated prior to implantation, current practice is
frequently not to do so. Indeed, successful PCI has been
demonstrated post-implantation [7-9], as both technologies
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allow access to the coronary ostia. The presence of con-
comitant CAD has been associated with adverse procedural
outcomes in sAVR [10,11] and now also in TAVI [5]. In
this higher risk cohort, with a mean age in excess of the
‘normal’ population with chronic stable angina, we must
carefully evaluate any coronary artery lesion’s signifi-
cance in terms of the possibly greater risks of PCI
and the impact on the planned valvular intervention.
Considerations in pre-transcatheter aortic valve
implantation percutaneous coronary intervention
Among the possible advantages of revascularization
prior to TAVI may be a protective effect against the
ischemic burden of the procedure, including as it does
periods of hypotension. The absence of contractile reserve
is associated with increased mortality after sAVR [12], and
significant stenoses not intervened upon could contribute
to this. Surgical revascularization for multi-vessel coronary
artery disease has been found to be an independent factor
predictive of improvement of left ventricular ejection
fraction (LVEF) after sAVR [13], and similar benefits for
revascularization by PCI may exist. Improving coronary
flow in symptomatic patients with significant flow-limiting
stenoses may maximize this beyond the valvular interven-
tion. Wave intensity analysis of coronary flow has demon-
strated marked reduction in the diastolic suction wave in
aortic stenosis (the dominant wave in coronary perfusion
[14]), which significant stenosis may impair further [15].
The risks of PCI are well described: death, myocardial
infarction, coronary artery bypass grafting (CABG), stroke,
vascular access complications, renal insufficiency, allergy
and stroke/TIA [16,17]. PCI is also associated with an
incidence of stent thrombosis of up to 1% with significant
mortality [18,19]. The presence of severe aortic stenosis
could have a detrimental effect upon the ability to
withstand these. Indeed, the hypotension experienced by
patients during the TAVI procedure (especially during
rapid right ventricular pacing) may actually increase the
risk of stent thrombosis. There has been increasing
recognition recently of the adverse outcomes associated
with major bleeding post-PCI [20,21]. Current opinion is
to continue aspirin for life and clopidogrel for one month
after bare metal stenting and 12 months after insertion of
a drug-eluting stent. This would possibly impact upon
bleeding complications in transfemoral, subclavian and
transaortic TAVI and would certainly be of concern in
patients undergoing TAVI via the transapical approach,
given the direct myocardial access required. Angiography
in the 24 hours, or even the 5 days, prior to sAVR has
been shown to be associated with acute kidney injury
post-operatively [22]. These risks may also exist if PCI and
TAVI are inadequately separated or combined in a hybrid
procedure. Finally, patients would require two admissions
with attendant implications to cost and risk. This
latter consideration might be offset against the possible
reduction in length of stay in the post-TAVI period.
Why do we need a randomized trial?
The data on coronary artery disease in TAVI and PCI in this
context is certainly provocative, but there are several major
limitations, given that the studies are all nonrandomized,
registry-type with relatively small sample sizes.
The lack of data on pre-procedural revascularization
has led to some variability between centers on the level of
coronary interventions undertaken prior to implantation.
A retrospective analysis by Masson et al. stratified TAVI
patients according to myocardium at risk due to coronary
artery disease, finding no difference in 30-day or 1-year
mortality between the groups [4]. However the small
group sizes involved would have required a mortality
difference between even the two most extreme groups at
30 days of greater than one third to gain significance,
limiting our use of this data. The access approach used
was not included in their risk model, an important
omission given the known differences in risk profiles
between, for example, TF-TAVI and TA-TAVI cohorts.
In the German TAVI registry, CAD was defined as
previous revascularization (either PCI or CABG) OR a
stenosis of ≥50% and was noted in 62% of 1,382 patients.
These patients had a greater in-hospital mortality
(10.0 versus 5.5%, P <0.01), required more frequent
cardio-pulmonary resuscitation (7.8 versus 3.5%, P <0.01)
and suffered greater 30-day mortality (log rank P = 0.041).
But there were significant differences in the group demo-
graphics: more frequent peripheral vascular disease, lower
left ventricular (LV) ejection fraction and higher logistic
EuroScores in patients with CAD [23]. The Italian
CoreValve registry noted that in patients with critical
ostial disease, myocardial infarction (MI) within 12 months
of TAVI was greater in those patients who were not revas-
cularized prior to TAVI [24]. A recent meta-analysis of the
effects of CAD upon outcome in the midterm showed no
effect; but again, of seven included studies, five defined
CAD as previous revascularization, and the remaining two
used 50% stenosis severity [25].
The presence of pre-existing treated coronary artery
disease has been identified as an adverse risk factor for
procedural and long term outcome [5]. With regards to
the effects of pre-TAVI PCI, Masson and colleagues
performed a sub-analysis of just 15 patients in whom
PCI was performed at the discretion of the individual
cardiologist: the resultant selection bias in turn clouds
the interpretation of any findings. The mortality in the
overall group one-year after TAVI was reported as 77.9%
and was found to be 80% in those with pre-emptive
PCI - though no comparison between the two cohorts
was performed [4]. Abdel Wahab et al. reported that
55 patients who underwent PCI prior to TAVI showed no
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difference in adverse events at either 30 days (2% versus
6%; P = 0.27) or 6 months (9% versus 14%; P = 0.42) when
compared to a group undergoing isolated TAVI [26]. The
feasibility of PCI for CAD in patients with severe AS
has been demonstrated by Goel et al. in a cohort of
258 patients over a 10-year period with a favorable
comparison with propensity matched patients without
the aortic disease [27].
There has been a rapid, global expansion in the use of
TAVI to treat aortic stenosis in patients who are not
candidates for sAVR. The efficacy of this technique
has been successfully demonstrated in randomized,
controlled trials [28,29] and in large registries [30,31],
and there is now a need to improve patient safety
and outcome, including how to manage patients with
concomitant CAD. Given the paucity of data on the
issue and variation in practice and recommendations
we feel a randomized controlled trial (RCT) is essential
for safe evidence-based practice. ACTIVATION is the first
randomized controlled trial of elective PCI prior to TAVI.
Its findings will help define the optimum revascularization
strategy in this procedure and help create evidence-based
guidelines on this controversial issue.
Methods/Design
Hypothesis, design and end points
ACTIVATION is a prospective, randomized, open-label
trial that aims to test the hypothesis that revascularization
of significant coronary artery disease by PCI prior to TAVI
(Test arm) will result in a rate of mortality and re-
hospitalization at 12 months that is non-inferior to TAVI
without such revascularization (control). Because the
control patients in this study are receiving a CE/FDA
approved valve replacement, a trial arm comparison would
not be likely to demonstrate superiority in either direction.
The trial has an intentional non-inferiority design. The
safety of TAVI with revascularization performed as deemed
necessary by the Heart Team has been demonstrated in
previous trials and registries [29,30,32]. From the available
data detailed in the statistical design section, our hypo-
thesis is that the no PCI strategy will have comparable
effectiveness to the PCI (the active control) strategy,
hopefully helping the cardiology community decide
whether the extra procedure of pre-TAVI PCI can be
safely avoided. From an ethical standpoint, a sham
procedure in the no PCI arm could not be countenanced.
Given the complexities of the TAVI procedure and the
recommended Heart Team approach, we could not
blind operators as to whether patients had undergone
revascularization or not. To minimize bias towards the
null, we have robust inclusion/exclusion criteria and clear
end-point definitions and boundaries. Any deviation
from the protocol in delivery of strategy will be carefully
recorded, including any concomitant therapies.
Patient population
Patient eligibility will be confirmed by the study investiga-
tors according to the inclusion and exclusion criteria
in Table 1.
Primary endpoint
The primary endpoint is a composite of mortality and
rehospitalization at 12 months since randomization.
Mortality is defined as death due to any cause, the exact
nature and date of which will be recorded. All deaths
will be considered cardiovascular-related unless there is
documentation to the contrary.
Secondary endpoints
These consist of:
i) Mortality at 30 days and 12 months post-TAVI
ii) Major adverse cardiovascular or cerebrovascular
event (MACCE) at 30 days and 12 months
iii)Acute myocardial infarction (MI) at 30 days and
12 months
iv) Stroke at 30 days and 12 months
v) Repeat revascularization by either PCI or CABG
vi)Hospitalization for heart failure at 30 days and
12 months
vii) Procedural complications (ventricular fibrillation
(VF) or ventricular tachycardia (VT) requiring
cardioversion
viii) Requirement of cardiopulmonary bypass
ix) Cardiopulmonary arrest requiring cardiopulmonary
resuscitation (CPR) and/or assisted ventilatory
support
x) Procedural success
xi)Bleeding complications
xii) Access site complications
xiii)Cerebrovascular events
xiv) Acute kidney injury
xv) Duration of hospital stay
xvi) Quality of life
xvii) Anginal burden
xviii) 6-minute walk test
The definitions are in accordance with the Valve
Academic Research Consortium (VARC) guidelines and
its update and are specified in Table 2 [33].
Ethics
Ethics review was approved by United Kingdom National
Research Ethics Committee (London Dulwich) (11/LO/
1596).
Randomization
Randomization will take place once the patient has
provided written, informed consent. This will be performed
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via an online portal. Randomization of the treatment
assignment is based on the block method using randomly
varying block sizes and will be stratified by center. Once
the patient is randomized s/he will be monitored for the
duration of the follow-up irrespective of subsequent
clinical management. The intended timeframe for PCI
should be stated at randomization. After PCI the patient
should receive dual anti-platelet therapy for 30 days - one
of which can then stop if the patient receives a bare-metal
stent (BMS). All PCI patients should undergo TAVI within
the 2 weeks after this 30-day post-PCI time point.
Any clinical events which occur in the test arm
during this period will be attributed to the percutan-
eous revascularization on an intention-to-treat-basis.
The flow diagram in Figure 1 illustrates the recruit-
ment and study process.
Trial conduct
ACTIVATION will be conducted at up to 20 hospitals
in Europe providing TAVI using the Edwards system.
Trial administration and data management will be
carried out by an independent clinical trial organization,
the European Cardiovascular Research Center, Massy,
France. The trial is registered at www.controlled-trials.
com (ISRCTN75836930).
Procedural details
Percutaneous coronary intervention
The percutaneous coronary intervention in the test arm
should be performed according to current local best
practice. The use of the OMEGA bare metal stent
(Boston Scientific Inc, Natick, MA, USA) or PROMUS
family of drug-eluting stents (DES; Boston Scientific Inc,
Natick, MA, USA) is mandatory. It is strongly recom-
mended that patients should be pre-treated with aspirin
300 mg and either clopidgrel 600 mg, prasugrel 60 mg, or
ticagrelor 180 mg as per local guidelines. Patients should
also receive appropriate anticoagulant therapy during
the PCI. The route of access (radial or femoral), use of fur-
ther interventional techniques (for example, intravascular
ultrasound, rotablation, laser atherectomy etcetera) and
PCI equipment are at the discretion of the operator.
Post-procedure aspirin should be continued at a mainten-
ance of 75 mg o.d.. Patients should receive either
Table 1 Eligibility criteria for the percutaneous coronary intervention prior to transcatheter aortic valve implantation
(ACTIVATION) trial
Inclusion criteria
Definition
• Patients ≥18 years of age
• Severe aortic stenosis, as defined by • Peak transvalvular gradient of ≥40 mmHg on transthoracic
echocardiography (TTE), transesophageal echocardiography (TOE)
or dobutamine stress echocardiography (DSE)
• Aortic valve area of <1.0 cm2
• Symptoms suggestive of aortic stenosis Dyspnea, syncope etc. but not pre-dominantly angina
• Deemed of prohibitive risk for open aortic valve replacement by a TAVI
multidisciplinary team (MDT) and accepted for TAVI by said TAVI MDT.
Significant coronary artery disease • ≥1 stenosis of ≥70% in a major epicardial artery deemed suitable
for PCI (≥50% if protected left main stem or vein graft)
• Undergoing TAVI via any accepted approach Transfemoral, transapical, subclavian or transaortic
• Written informed consent
Exclusion Criteria Definition
• Recent acute coronary syndrome Within 30 days of randomization
• Unprotected left main stem disease
• Significant angina CCS class ≥3
• Pregnancy
• Active internal bleeding (except menstruation)
• Allergy to heparin or GPIIb/IIIa inhibitors
• Thrombocytopenia cells/mm3) Platelet count <100,000
• Patients who have previously been enrolled in this study
• Patients who are currently enrolled in any other study where involvement in
ACTIVATION would involve deviation from either protocol
TAVI, transcatheter aortic valve implantation; CCS, Canadian Cardiac Society; GpIIb/IIIa, glycoprotein IIb/IIIa.
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clopidogrel 75 mg o.d., Prasugrel 10 mg o.d. or Ticagrelor
90 mg b.d. for 30 days after PCI for BMS or 6 months for
DES as per local guidelines.
Transcatheter aortic valve implantation
Patients should be accepted for TAVI by a multidisciplinary
team including both an interventional cardiologist
and a cardiothoracic surgeon. The procedure should
use the balloon-expandable Edwards SAPIEN XT
prosthesis (Edwards Lifesciences, Irvine, CA, USA). The
choices of prosthesis size and access route (transfemoral,
transapical or transaortic) are to be left to the discretion
of the operating team. Equally the intraprocedural
details (local versus general anesthetic, perioperative
imaging etcetera) should proceed as per usual practice
at the enrolling center. Both aspirin and clopidogrel
should be continued for at least 6 months after TAVI
implantation with lifelong single anti-platelet therapy
thereafter.
Data collection and monitoring
Data will be collected at baseline from enrolled patients
including demographics, past medical history, previous
cardiac investigations and current medication. Patients will
undergo transthoracic ± transesophageal echocardiography
at baseline, post-procedure, 1 month and 12 months.
Twelve-lead electrocardiograms will be obtained at the
same time points, with additional traces in the test arm
pre- and post-PCI and in either arm after any clinical event
thought to represent myocardial infarction and before/after
any subsequent revascularization procedure. In addition
to routine blood tests, a full blood count will be taken
pre- and post-PCI.
Prospective monitoring of adverse and clinical events
starts at randomization and continues until 12 months.
Patients should be followed up to hospital discharge
following PCI. All MACCE will be documented by the
research coordinator using the clinical event data form.
The same applies for the TAVI procedure. Patients will
be followed up at 30 days and 12 months for anginal
burden using the Seattle Angina Questionnaire and
other end-points. Mortality data will be obtained from
the Office of National Statistics in England and Wales,
the General Register Office in Scotland and from the
appropriate authority in other countries.
All MACCE and other serious adverse events will
be recorded in the electronic Case Record Form and
reported to the coordinating center within 3 working
days of first identification. On receipt of notification
of any trial adverse or clinical event, the coordinating
center will request additional details, specific to the
nature of the event. These episodes will be carefully
monitored by the trial coordinator and will form part
of the information provided at regular intervals to the
Clinical Events and Data Monitoring Committees. The
study site will also notify their ethics committee and
institutional clinical risk management team according
to their local policy. The Clinical Events Committee
will be blinded to treatment and will consider each
MACCE or adverse event reported and ratify occurrence of
an endpoint according to the study definitions (according
to a majority).
Statistical consideration
Sample size determination
No randomized trials have been performed of elective
PCI versus no PCI in patients undergoing TAVI. In a
recent nonrandomized registry, Masson et al. reported a
1-year mortality of 20% in 15 patients who underwent
PCI prior to TAVI - similar to those who did not at
22.1% [4] - despite the presence of existing coronary disease
having been shown to increase mortality in patients
undergoing TAVI from 18.4 to 35.7% [5].
With the postulation that improved coronary perfusion
may protect against some of the ischemic/hypotensive
procedural complications of the TAVI procedure, an
improvement in rate of mortality seems likely. PCI may
Table 2 Endpoint definitions
End-point Definition
Mortality All-cause death
Cardiovascular mortality All deaths unless otherwise clearly
documented to be related to
another cause (for example, trauma,
cancer, suicide etcetera)
Myocardial infarction (MI) Peri-procedural MI related to TAVI
(≤72 h after the TAVI)
Spontaneous MI (>72 h after TAVI)
MI related to PCI (type 4a)
MI related to PCI due to stent
thrombosis (type 4b)
Cerebrovascular event Stroke
Transient ischemic attack
Bleeding complication Life-threatening or disabling
Major
Minor
Access site complication Major
Minor
Acute kidney injury As per
AKIN classification in VARC2 [34]
Stage 1
Stage 2
Stage 3
Major adverse cardiac and
cerebrovascular events
(MACCE)
Combined cardiovascular mortality, MI,
stroke and further revascularization
TAVI, transcatheter aortic valve implantation; PCI, percutaneous coronary
intervention, AKIN, acute kidney injury network; VARC2, Valve Academic
Research Consortium second guidelines [34].
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lead to restenosis of the stent, requiring rehospitaliza-
tion in 5% of patients over 12 months. The rate of
rehospitalization with stable angina, acute coronary
syndrome or ischemia-related heart failure requiring
treatment, including possible PCI, is thought to be in
the region of 15% in all patients with CAD. The feasi-
bility assumptions for 12-month mortality are 30% in
the control (TAVI only) arm and 20% in the test
(TAVI + PCI) arm, with similar rates of hospitalization
at 15% in both. Based on the above assumptions, we
performed sample size simulations and the simulated
results show that with a non-inferiority margin of 7.5%
and a loss to follow up of 5%, the sample size of 310
patients will have at least 88.8% power to demonstrate
non-inferiority of TAVR following PCI compared with
TAVR without PIC in the primary endpoint.
Statistical analysis
For the primary endpoint analysis, cumulative event rate
will be calculated using the Kaplan-Meier estimates, and
the Greenwood standard errors for these estimates. A
95% one-sided upper confidence limit will be computed
for the difference in the primary composite outcome of
mortality of rehospitalization at 12 months between
arms (Test - Control). The Test arm (PCI) will be judged
not inferior to the Control arm (no PCI) if the upper
confidence limit is less than 7.5% - the predetermined
non-inferiority margin. This was chosen based upon
expert opinion and precedent (PARTNER cohort A [29]).
In addition to formal analysis of non-inferiority endpoints,
the Kaplan-Meier curves will be presented and compared
by log rank test by treatment group and hazard ratio and
its 95% confidence interval will be calculated using Cox
Figure 1 Flow chart. (TAVI, transcatheter aortic valve implantation; MDT, multidisciplinary team; LAD, left anterior descending artery; Cx, circumflex
artery; RCA, right coronary artery; LMS, left main stem; SVG, saphenous vein graft; PCI, percutenaous coronary intervention; BMS, bare metal stent; DES,
drug eluting stent).
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regression model. Also, the combination of the all cause
mortality and time to first recurrent hospitalization will be
analyzed using the unmatched win ratio approach [35].
For secondary time-to-event outcomes, event rates
at 30 and 365 days will be calculated using the
Kaplan-Meier method and compared by log rank test.
Their hazard ratios will be estimated using Cox regression
model. Outcomes with repeated measurements will be
analyzed using generalized linear mixed models. Con-
tinuous variables will be summarized using number of
observations, median (interquartile range) or mean (SD)
depending on variable distributions, whereas categorical
variables will be summarized by the number and per-
centage of events. Chi-square tests and Mann-Whitney
methods will also be used for comparative purposes. All
analyses will be performed both on intention to treat and
as treated populations.
Discussion
Trial status
The trial is now actively recruiting at centers in the
United Kingdom, France and Germany.
Through investigator meetings and feedback, a few
recurrent operational issues have arisen. Many centers
have an admission for completion of all TAVI-related
tests prior to a multidiscliplinary meeting decision at a
later date. This then requires a further attendance to
hospital for consent, baseline assessments and
randomization. This can be expedited if a Heart Team can
convene for a decision while the patient is an inpatient so
that they can be approached, consented, etcetera.
Regarding the consent process, this target population
is often rather elderly and may, quite appropriately,
be apprehensive regarding the TAVI procedure. So
investigators must carefully and simply explain the
trial and the consent process. Care must also be
taken in assessment of the level of angina given its
importance in the inclusion/exclusion criteria.
We are optimistic that the trial has achievable enrollment
targets and will answer an important question in this
nascent field.
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